Compare GOODO & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
| Metric | GOODO | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2003 | 2025 |
| Metric | GOODO | BCTXL |
|---|---|---|
| Price | $19.73 | $0.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 13.2K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $113.06 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $19.42 | $0.61 |
| 52 Week High | $22.20 | $1.40 |
| Indicator | GOODO | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 24.07 | 46.40 |
| Support Level | $19.61 | $0.75 |
| Resistance Level | $20.18 | $1.11 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 4.25 | 6.25 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.